PubMed:33871211 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/33871211","sourcedb":"PubMed","sourceid":"33871211","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/33871211","text":"Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis: A randomized controlled trial.\nBACKGROUND: Methotrexate is the most commonly used drug in the treatment of psoriasis with good efficacy and safety. Recently, weekly azathioprine pulse has been shown to be effective in this disease.\nAIM: The aim of this study is to compare the effectiveness and safety of weekly pulse doses of azathioprine and methotrexate for the treatment of chronic plaque psoriasis.\nMETHODS: In this randomized controlled trial, 80 patients with chronic plaque psoriasis were recruited. After detailed clinical and laboratory evaluation, patients were randomized to 2 groups to receive either weekly 300 mg azathioprine (n = 40) or 15 mg methotrexate every week (n = 40) for 20 weeks, following which the response to treatment and adverse effects were assessed. The patients were then followed up every 4 weeks for 3 months to determine any relapse.\nRESULTS: Overall, 48 (60%) patients achieved PASI 75, while 36 (45%) and 59 (73.8%) patients achieved PASI 100 and 50, respectively. On intention to treat analysis, PASI ≥ 75 was achieved in 47.5% (19/40) patients in group 1 compared to 85% (34/40) patients in group 2 (p \u003c 0.001). However, on per protocol analysis, PASI ≥ 75 was achieved in 86% (19/22) patients in group 1 and 92% (34/37) patients in group 2 (p = 0.497). Minor clinical and biochemical adverse effects were noted in both the groups, which were comparable. One (7.7%) patient in group 1 and 4 (17.4%) in group 2 relapsed during follow-up.\nLIMITATIONS: Limitations of study include small sample size and short follow-up.\nCONCLUSION: Weekly azathioprine pulse appears to be beneficial in the management of chronic plaque psoriasis. However, it is less effective than weekly methotrexate. It can thus be of use as a therapeutic option in patients with contraindication to methotrexate or other similar agents in this disease.","tracks":[{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":82,"end":91},"obj":"DP"},{"id":"T2","span":{"begin":200,"end":209},"obj":"DP"},{"id":"T3","span":{"begin":486,"end":495},"obj":"DP"},{"id":"T4","span":{"begin":575,"end":584},"obj":"DP"},{"id":"T5","span":{"begin":1751,"end":1760},"obj":"DP"},{"id":"T6","span":{"begin":33,"end":45},"obj":"CI"},{"id":"T7","span":{"begin":437,"end":449},"obj":"CI"},{"id":"T8","span":{"begin":752,"end":764},"obj":"CI"},{"id":"T9","span":{"begin":1804,"end":1816},"obj":"CI"},{"id":"T10","span":{"begin":1901,"end":1913},"obj":"CI"},{"id":"T11","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T12","span":{"begin":136,"end":148},"obj":"CI"},{"id":"T13","span":{"begin":258,"end":270},"obj":"CI"},{"id":"T14","span":{"begin":420,"end":432},"obj":"CI"},{"id":"T15","span":{"begin":721,"end":733},"obj":"CI"},{"id":"T16","span":{"begin":1671,"end":1683},"obj":"CI"}],"attributes":[{"subj":"T1","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T2","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T3","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T4","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T5","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T6","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T7","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T8","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T9","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T10","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T11","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T12","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T13","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T14","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T15","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T16","pred":"source","obj":"yangbin123xm_800_3"}]},{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":136,"end":148},"obj":"CI"},{"id":"T2","span":{"begin":33,"end":45},"obj":"CI"},{"id":"T3","span":{"begin":437,"end":449},"obj":"CI"},{"id":"T4","span":{"begin":752,"end":764},"obj":"CI"},{"id":"T5","span":{"begin":1804,"end":1816},"obj":"CI"},{"id":"T6","span":{"begin":1901,"end":1913},"obj":"CI"},{"id":"T7","span":{"begin":258,"end":270},"obj":"CI"},{"id":"T8","span":{"begin":420,"end":432},"obj":"CI"},{"id":"T9","span":{"begin":721,"end":733},"obj":"CI"},{"id":"T10","span":{"begin":1671,"end":1683},"obj":"CI"},{"id":"T11","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T12","span":{"begin":82,"end":91},"obj":"DP"},{"id":"T13","span":{"begin":200,"end":209},"obj":"DP"},{"id":"T14","span":{"begin":486,"end":495},"obj":"DP"},{"id":"T15","span":{"begin":575,"end":584},"obj":"DP"},{"id":"T16","span":{"begin":1751,"end":1760},"obj":"DP"}],"attributes":[{"subj":"T1","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T2","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T3","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T4","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T5","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T6","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T7","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T8","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T9","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T10","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T11","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T12","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T13","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T14","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T15","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T16","pred":"source","obj":"chenxin_473849_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"yangbin123xm_800_3","color":"#93bdec","default":true},{"id":"chenxin_473849_800_3","color":"#d7ec93"}]}]}}